25 XP   0   0   10

Axsome Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Axsome together

PenkeI guess you are interested in Axsome Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Axsome Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Axsome Therapeutics Inc

I send you an email if I find something interesting about Axsome Therapeutics Inc.

Quick analysis of Axsome (30 sec.)










What can you expect buying and holding a share of Axsome? (30 sec.)

How much money do you get?

How much money do you get?
$1.76
When do you have the money?
1 year
How often do you get paid?
13.2%

What is your share worth?

Current worth
$4.03
Expected worth in 1 year
$5.75
How sure are you?
31.6%

+ What do you gain per year?

Total Gains per Share
$3.48
Return On Investment
5.3%

For what price can you sell your share?

Current Price per Share
$65.72
Expected price per share
$56.75 - $98.40
How sure are you?
50%

1. Valuation of Axsome (5 min.)




Live pricePrice per Share (EOD)

$65.72

Intrinsic Value Per Share

$-29.27 - $-34.12

Total Value Per Share

$-25.24 - $-30.09

2. Growth of Axsome (5 min.)




Is Axsome growing?

Current yearPrevious yearGrowGrow %
How rich?$190.9m$74.2m$138.5m65.1%

How much money is Axsome making?

Current yearPrevious yearGrowGrow %
Making money-$59.8m-$49.4m-$10.3m-17.3%
Net Profit Margin-100.3%-260.0%--

How much money comes from the company's main activities?

3. Financial Health of Axsome (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#263 / 1016

Most Revenue
#124 / 1016

Most Profit
#914 / 1016

Most Efficient
#574 / 1016

What can you expect buying and holding a share of Axsome? (5 min.)

Welcome investor! Axsome's management wants to use your money to grow the business. In return you get a share of Axsome.

What can you expect buying and holding a share of Axsome?

First you should know what it really means to hold a share of Axsome. And how you can make/lose money.

Speculation

The Price per Share of Axsome is $65.72. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Axsome.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Axsome, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.03. Based on the TTM, the Book Value Change Per Share is $0.43 per quarter. Based on the YOY, the Book Value Change Per Share is $2.74 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.44 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Axsome.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.08-3.2%-1.26-1.9%-0.99-1.5%-0.77-1.2%-0.49-0.7%
Usd Book Value Change Per Share-1.66-2.5%0.430.7%2.744.2%0.200.3%0.110.2%
Usd Dividend Per Share0.000.0%0.440.7%0.000.0%0.090.1%0.050.1%
Usd Total Gains Per Share-1.66-2.5%0.871.3%2.744.2%0.290.4%0.150.2%
Usd Price Per Share79.59-70.76-50.36-56.83-31.82-
Price to Earnings Ratio-9.56--25.16--12.51--23.35--15.00-
Price-to-Total Gains Ratio-48.01--96.81-890.29-25.34--41.10-
Price to Book Ratio19.74-17.59-74.89-41.68-35.10-
Price-to-Total Gains Ratio-48.01--96.81-890.29-25.34--41.10-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share65.72
Number of shares15
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.440.09
Usd Book Value Change Per Share0.430.20
Usd Total Gains Per Share0.870.29
Gains per Quarter (15 shares)13.064.34
Gains per Year (15 shares)52.2417.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12626425127
2535294112424
37977146163641
4106103198214858
5132129250276075
6159155302327292
71851803543784109
82122064064396126
923823245848108143
1026525851053120160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.038.00.00.0%0.038.01.00.0%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%8.012.00.040.0%12.024.02.031.6%12.025.02.030.8%
Dividend per Share3.00.01.075.0%5.00.07.041.7%5.00.015.025.0%5.00.033.013.2%5.00.034.012.8%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%8.012.00.040.0%12.024.02.031.6%12.025.02.030.8%

Fundamentals of Axsome

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Fundamental data was last updated by Penke on 2024-04-11 01:45:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Axsome Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Axsome earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Axsome to the Biotechnology industry mean.
  • A Net Profit Margin of -137.9% means that $-1.38 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Axsome Therapeutics Inc:

  • The MRQ is -137.9%. The company is making a huge loss. -2
  • The TTM is -100.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-137.9%TTM-100.3%-37.6%
TTM-100.3%YOY-260.0%+159.7%
TTM-100.3%5Y-72.1%-28.2%
5Y-72.1%10Y-37.9%-34.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-137.9%-199.6%+61.7%
TTM-100.3%-213.0%+112.7%
YOY-260.0%-279.3%+19.3%
5Y-72.1%-438.4%+366.3%
10Y-37.9%-605.5%+567.6%
1.1.2. Return on Assets

Shows how efficient Axsome is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Axsome to the Biotechnology industry mean.
  • -16.8% Return on Assets means that Axsome generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Axsome Therapeutics Inc:

  • The MRQ is -16.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.8%TTM-10.2%-6.5%
TTM-10.2%YOY-26.0%+15.8%
TTM-10.2%5Y-18.1%+7.8%
5Y-18.1%10Y-24.4%+6.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.8%-13.5%-3.3%
TTM-10.2%-12.9%+2.7%
YOY-26.0%-11.8%-14.2%
5Y-18.1%-14.1%-4.0%
10Y-24.4%-16.0%-8.4%
1.1.3. Return on Equity

Shows how efficient Axsome is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Axsome to the Biotechnology industry mean.
  • -51.7% Return on Equity means Axsome generated $-0.52 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Axsome Therapeutics Inc:

  • The MRQ is -51.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -27.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-51.7%TTM-27.2%-24.4%
TTM-27.2%YOY-162.9%+135.7%
TTM-27.2%5Y-63.6%+36.3%
5Y-63.6%10Y-71.0%+7.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-51.7%-16.9%-34.8%
TTM-27.2%-16.1%-11.1%
YOY-162.9%-15.1%-147.8%
5Y-63.6%-19.9%-43.7%
10Y-71.0%-20.9%-50.1%

1.2. Operating Efficiency of Axsome Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Axsome is operating .

  • Measures how much profit Axsome makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Axsome to the Biotechnology industry mean.
  • An Operating Margin of -157.9% means the company generated $-1.58  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Axsome Therapeutics Inc:

  • The MRQ is -157.9%. The company is operating very inefficient. -2
  • The TTM is -100.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-157.9%TTM-100.4%-57.5%
TTM-100.4%YOY-233.7%+133.3%
TTM-100.4%5Y-66.8%-33.6%
5Y-66.8%10Y-35.2%-31.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-157.9%-295.1%+137.2%
TTM-100.4%-225.8%+125.4%
YOY-233.7%-288.4%+54.7%
5Y-66.8%-477.4%+410.6%
10Y-35.2%-625.6%+590.4%
1.2.2. Operating Ratio

Measures how efficient Axsome is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.46 means that the operating costs are $2.46 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Axsome Therapeutics Inc:

  • The MRQ is 2.456. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.966. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.456TTM1.966+0.490
TTM1.966YOY3.087-1.121
TTM1.9665Y1.010+0.955
5Y1.01010Y0.532+0.479
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4563.090-0.634
TTM1.9663.264-1.298
YOY3.0873.783-0.696
5Y1.0105.679-4.669
10Y0.5327.894-7.362

1.3. Liquidity of Axsome Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Axsome is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.63 means the company has $3.63 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Axsome Therapeutics Inc:

  • The MRQ is 3.632. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.910. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.632TTM3.910-0.278
TTM3.910YOY3.177+0.732
TTM3.9105Y5.276-1.366
5Y5.27610Y4.959+0.317
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6323.914-0.282
TTM3.9104.220-0.310
YOY3.1775.388-2.211
5Y5.2766.045-0.769
10Y4.9596.406-1.447
1.3.2. Quick Ratio

Measures if Axsome is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Axsome to the Biotechnology industry mean.
  • A Quick Ratio of 3.46 means the company can pay off $3.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Axsome Therapeutics Inc:

  • The MRQ is 3.464. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.766. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.464TTM3.766-0.302
TTM3.766YOY3.034+0.732
TTM3.7665Y5.199-1.433
5Y5.19910Y4.853+0.346
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4643.572-0.108
TTM3.7663.998-0.232
YOY3.0345.390-2.356
5Y5.1995.969-0.770
10Y4.8536.287-1.434

1.4. Solvency of Axsome Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Axsome assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Axsome to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.68 means that Axsome assets are financed with 67.5% credit (debt) and the remaining percentage (100% - 67.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Axsome Therapeutics Inc:

  • The MRQ is 0.675. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.621. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.675TTM0.621+0.054
TTM0.621YOY0.739-0.118
TTM0.6215Y0.506+0.115
5Y0.50610Y0.648-0.142
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6750.336+0.339
TTM0.6210.334+0.287
YOY0.7390.269+0.470
5Y0.5060.366+0.140
10Y0.6480.390+0.258
1.4.2. Debt to Equity Ratio

Measures if Axsome is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Axsome to the Biotechnology industry mean.
  • A Debt to Equity ratio of 208.0% means that company has $2.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Axsome Therapeutics Inc:

  • The MRQ is 2.080. The company is just not able to pay all its debts with equity.
  • The TTM is 1.746. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.080TTM1.746+0.334
TTM1.746YOY4.771-3.025
TTM1.7465Y1.841-0.095
5Y1.84110Y1.633+0.208
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0800.382+1.698
TTM1.7460.396+1.350
YOY4.7710.335+4.436
5Y1.8410.434+1.407
10Y1.6330.465+1.168

2. Market Valuation of Axsome Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Axsome generates.

  • Above 15 is considered overpriced but always compare Axsome to the Biotechnology industry mean.
  • A PE ratio of -9.56 means the investor is paying $-9.56 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Axsome Therapeutics Inc:

  • The EOD is -7.890. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.555. Based on the earnings, the company is expensive. -2
  • The TTM is -25.163. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.890MRQ-9.555+1.665
MRQ-9.555TTM-25.163+15.608
TTM-25.163YOY-12.506-12.658
TTM-25.1635Y-23.355-1.809
5Y-23.35510Y-15.001-8.354
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.890-2.259-5.631
MRQ-9.555-2.569-6.986
TTM-25.163-2.664-22.499
YOY-12.506-4.120-8.386
5Y-23.355-6.258-17.097
10Y-15.001-6.171-8.830
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Axsome Therapeutics Inc:

  • The EOD is -25.630. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -31.039. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -46.429. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-25.630MRQ-31.039+5.409
MRQ-31.039TTM-46.429+15.389
TTM-46.429YOY-21.106-25.323
TTM-46.4295Y-34.167-12.262
5Y-34.16710Y-22.663-11.504
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-25.630-2.924-22.706
MRQ-31.039-3.246-27.793
TTM-46.429-3.488-42.941
YOY-21.106-5.620-15.486
5Y-34.167-8.315-25.852
10Y-22.663-8.826-13.837
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Axsome is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 19.74 means the investor is paying $19.74 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Axsome Therapeutics Inc:

  • The EOD is 16.303. Based on the equity, the company is expensive. -2
  • The MRQ is 19.743. Based on the equity, the company is expensive. -2
  • The TTM is 17.593. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD16.303MRQ19.743-3.441
MRQ19.743TTM17.593+2.150
TTM17.593YOY74.892-57.299
TTM17.5935Y41.684-24.091
5Y41.68410Y35.103+6.581
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD16.3031.851+14.452
MRQ19.7432.090+17.653
TTM17.5932.095+15.498
YOY74.8922.844+72.048
5Y41.6843.466+38.218
10Y35.1033.815+31.288
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Axsome Therapeutics Inc.

3.1. Institutions holding Axsome Therapeutics Inc

Institutions are holding 83.034% of the shares of Axsome Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31RTW INVESTMENTS, LLC9.47685.5816448959600
2023-12-31Vanguard Group Inc7.80330.00643696766-32360-0.8678
2023-12-31BlackRock Inc6.83860.0066323974630525610.4024
2023-12-31Fairmount Funds Management LLC4.981819.84652360077188390.8047
2023-09-30Bvf Inc4.49844.0163213110000
2023-09-30Citadel Advisors Llc2.73490.01941295624841306185.18
2023-12-31Perceptive Advisors LLC2.19111.84411038019556370115.5136
2023-12-31Deep Track Capital, LP2.11082.6581000000-140745-12.338
2023-12-31RA Capital Management, LLC2.11081.2431100000000
2023-12-31State Street Corporation1.95080.0036924190565436.5168
2023-12-31Millennium Management LLC1.92080.031390996540692380.8925
2023-12-31FMR Inc1.86180.0054882027-976529-52.5424
2023-12-31Geode Capital Management, LLC1.73580.0069822304438095.6274
2023-12-31Alethea Capital Management, LLC1.587469.058752044-6750-0.8896
2023-12-31Pictet Asset Manangement SA1.47530.0614698932525038.122
2023-12-31Bellevue Group AG1.34120.773563537238850.6152
2023-12-31Morgan Stanley - Brokerage Accounts1.30740.0043619379320958107.5521
2023-12-31Jefferies Financial Group Inc1.18910.2925563335101401.833
2023-12-31Woodline Partners LP1.18660.486656216311005624.3429
2023-09-30Point72 Asset Management, L.P.1.12280.10855319376393413.661
Total 59.4255106.05428152576+1634138+5.8%

3.2. Funds holding Axsome Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.51070.00621189445-3719-0.3117
2024-02-29Vanguard Small Cap Index2.05990.056597585491280.9442
2024-03-28iShares Russell 2000 ETF1.84250.106487288035570.4092
2023-11-30Bellevue Healthcare Ord1.30714.749161924823176259.8117
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.20710.04565718634130.0723
2024-02-29Vanguard Small Cap Growth Index Inv1.15290.127454618460671.1233
2024-01-31Fidelity Small Cap Index0.76160.13136080757591.622
2023-12-31Pictet-Biotech P USD0.74981.7897355194-10171-2.7838
2023-12-31Eventide Healthcare & Life Sciences I0.73191.655534671200
2024-03-28iShares Russell 2000 Growth ETF0.65310.2119309403-360-0.1162
2024-02-29Delaware Small Cap Core I0.63550.33293010853010850
2024-03-28iShares Biotechnology ETF0.61420.3043290978-1202-0.4114
2023-12-31Pictet-Global Megatrend Sel I USD0.60990.1831288916-14439-4.7598
2023-12-31FIAM Small Cap Core Composite0.50040.4832237044-6300-2.5889
2024-01-31FIAM Small Cap Core CIT Cl B0.49720.5595235544-1500-0.6328
2024-02-29Fidelity Extended Market Index0.46290.046521929110310.4724
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.45670.042221634957002.7059
2023-09-30Fidelity Global Innovators Cl F0.45210.23822141833890.182
2023-12-31Hood River Small-Cap Growth Instl0.41870.8437198366164119.0193
2024-03-29Schwab US Small-Cap ETF™0.38360.084918171700
Total 18.007811.99788531063+543611+6.4%

3.3. Insider Transactions

Insiders are holding 17.122% of the shares of Axsome Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-01Mark L. JacobsonSELL2466277.24
2024-03-14Roger JeffsSELL2997669.7
2023-09-15Mark ColemanSELL1101675.19

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Axsome Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.6580.430-486%2.738-161%0.201-926%0.107-1646%
Book Value Per Share--4.0314.491-10%1.566+157%1.832+120%1.113+262%
Current Ratio--3.6323.910-7%3.177+14%5.276-31%4.959-27%
Debt To Asset Ratio--0.6750.621+9%0.739-9%0.506+34%0.648+4%
Debt To Equity Ratio--2.0801.746+19%4.771-56%1.841+13%1.633+27%
Dividend Per Share---0.441-100%0.002-100%0.089-100%0.047-100%
Eps---2.082-1.262-39%-0.988-53%-0.768-63%-0.486-77%
Free Cash Flow Per Share---0.641-0.769+20%-0.619-4%-0.523-18%-0.325-49%
Free Cash Flow To Equity Per Share---0.6410.978-166%0.883-173%0.449-243%0.244-363%
Gross Profit Margin--1.0001.689-41%1.262-21%1.190-16%1.100-9%
Intrinsic Value_10Y_max---34.125--------
Intrinsic Value_10Y_min---29.274--------
Intrinsic Value_1Y_max---2.732--------
Intrinsic Value_1Y_min---2.683--------
Intrinsic Value_3Y_max---8.732--------
Intrinsic Value_3Y_min---8.326--------
Intrinsic Value_5Y_max---15.365--------
Intrinsic Value_5Y_min---14.216--------
Market Cap3113445568.000-21%3770528496.0003351975672.000+12%2385774784.000+58%2692500336.800+40%1507503275.789+150%
Net Profit Margin---1.379-1.003-27%-2.600+89%-0.721-48%-0.379-72%
Operating Margin---1.579-1.004-36%-2.337+48%-0.668-58%-0.352-78%
Operating Ratio--2.4561.966+25%3.087-20%1.010+143%0.532+362%
Pb Ratio16.303-21%19.74317.593+12%74.892-74%41.684-53%35.103-44%
Pe Ratio-7.890+17%-9.555-25.163+163%-12.506+31%-23.355+144%-15.001+57%
Price Per Share65.720-21%79.59070.755+12%50.360+58%56.835+40%31.821+150%
Price To Free Cash Flow Ratio-25.630+17%-31.039-46.429+50%-21.106-32%-34.167+10%-22.663-27%
Price To Total Gains Ratio-39.646+17%-48.013-96.811+102%890.293-105%25.338-289%-41.098-14%
Quick Ratio--3.4643.766-8%3.034+14%5.199-33%4.853-29%
Return On Assets---0.168-0.102-39%-0.260+55%-0.181+8%-0.244+46%
Return On Equity---0.517-0.272-47%-1.629+215%-0.636+23%-0.710+37%
Total Gains Per Share---1.6580.871-290%2.740-161%0.289-673%0.154-1177%
Usd Book Value--190977000.000212775250.000-10%74203807.750+157%86791064.050+120%52718011.158+262%
Usd Book Value Change Per Share---1.6580.430-486%2.738-161%0.201-926%0.107-1646%
Usd Book Value Per Share--4.0314.491-10%1.566+157%1.832+120%1.113+262%
Usd Dividend Per Share---0.441-100%0.002-100%0.089-100%0.047-100%
Usd Eps---2.082-1.262-39%-0.988-53%-0.768-63%-0.486-77%
Usd Free Cash Flow---30369000.000-36415500.000+20%-29303226.750-4%-24799715.550-18%-15383660.263-49%
Usd Free Cash Flow Per Share---0.641-0.769+20%-0.619-4%-0.523-18%-0.325-49%
Usd Free Cash Flow To Equity Per Share---0.6410.978-166%0.883-173%0.449-243%0.244-363%
Usd Market Cap3113445568.000-21%3770528496.0003351975672.000+12%2385774784.000+58%2692500336.800+40%1507503275.789+150%
Usd Price Per Share65.720-21%79.59070.755+12%50.360+58%56.835+40%31.821+150%
Usd Profit---98651000.000-59809500.000-39%-49452149.250-50%-36934768.750-63%-22055469.816-78%
Usd Revenue--71530000.00067650000.000+6%12509276.500+472%16031855.300+346%8437818.579+748%
Usd Total Gains Per Share---1.6580.871-290%2.740-161%0.289-673%0.154-1177%
 EOD+3 -5MRQTTM+8 -28YOY+18 -185Y+10 -2610Y+11 -25

4.2. Fundamental Score

Let's check the fundamental score of Axsome Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.890
Price to Book Ratio (EOD)Between0-116.303
Net Profit Margin (MRQ)Greater than0-1.379
Operating Margin (MRQ)Greater than0-1.579
Quick Ratio (MRQ)Greater than13.464
Current Ratio (MRQ)Greater than13.632
Debt to Asset Ratio (MRQ)Less than10.675
Debt to Equity Ratio (MRQ)Less than12.080
Return on Equity (MRQ)Greater than0.15-0.517
Return on Assets (MRQ)Greater than0.05-0.168
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Axsome Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.237
Ma 20Greater thanMa 5073.654
Ma 50Greater thanMa 10078.431
Ma 100Greater thanMa 20079.108
OpenGreater thanClose69.440
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Depreciation and Amortization  2,017-4451,572171,589181,607-6,375-4,768



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets588,236
Total Liabilities397,259
Total Stockholder Equity190,977
 As reported
Total Liabilities 397,259
Total Stockholder Equity+ 190,977
Total Assets = 588,236

Assets

Total Assets588,236
Total Current Assets504,263
Long-term Assets83,973
Total Current Assets
Cash And Cash Equivalents 386,193
Net Receivables 94,820
Inventory 15,135
Other Current Assets 8,115
Total Current Assets  (as reported)504,263
Total Current Assets  (calculated)504,263
+/-0
Long-term Assets
Property Plant Equipment 7,618
Goodwill 12,042
Intangible Assets 53,286
Long-term Assets Other 11,027
Long-term Assets  (as reported)83,973
Long-term Assets  (calculated)83,973
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities138,854
Long-term Liabilities258,405
Total Stockholder Equity190,977
Total Current Liabilities
Short-term Debt 1,267
Accounts payable 40,679
Other Current Liabilities 96,908
Total Current Liabilities  (as reported)138,854
Total Current Liabilities  (calculated)138,854
+/-0
Long-term Liabilities
Long term Debt 178,070
Capital Lease Obligations Min Short Term Debt7,035
Long-term Liabilities Other 73,300
Long-term Liabilities  (as reported)258,405
Long-term Liabilities  (calculated)258,405
+/- 0
Total Stockholder Equity
Common Stock5
Retained Earnings -835,571
Other Stockholders Equity 1,026,543
Total Stockholder Equity (as reported)190,977
Total Stockholder Equity (calculated)190,977
+/-0
Other
Capital Stock5
Cash and Short Term Investments 386,193
Common Stock Shares Outstanding 47,330
Liabilities and Stockholders Equity 588,236
Net Debt -199,821
Net Invested Capital 369,047
Net Working Capital 365,409
Property Plant and Equipment Gross 7,618
Short Long Term Debt Total 186,372



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302013-12-31
> Total Assets 
2,097
0
2,786
0
6,875
6,138
49,076
45,148
40,008
34,918
38,213
46,412
39,043
32,618
35,556
27,939
21,725
16,126
15,379
43,901
54,778
44,440
220,550
197,801
190,990
203,629
186,134
166,904
143,265
116,599
-338,357
88,560
180,559
338,958
331,476
389,179
611,638
600,857
588,236
588,236600,857611,638389,179331,476338,958180,55988,560-338,357116,599143,265166,904186,134203,629190,990197,801220,55044,44054,77843,90115,37916,12621,72527,93935,55632,61839,04346,41238,21334,91840,00845,14849,0766,1386,87502,78602,097
   > Total Current Assets 
0
0
2,744
0
6,667
4,965
49,033
45,066
39,917
34,755
37,999
46,199
38,837
32,419
35,300
27,754
21,539
15,944
15,215
43,759
54,568
44,236
220,379
197,623
190,819
203,272
184,025
165,035
141,655
115,024
86,518
86,830
103,978
252,383
245,641
304,449
519,686
511,763
504,263
504,263511,763519,686304,449245,641252,383103,97886,83086,518115,024141,655165,035184,025203,272190,819197,623220,37944,23654,56843,75915,21515,94421,53927,75435,30032,41938,83746,19937,99934,75539,91745,06649,0334,9656,66702,74400
       Cash And Cash Equivalents 
2,088
0
2,618
0
6,414
4,621
48,036
44,078
38,752
33,888
36,618
45,020
37,994
31,673
34,021
26,633
20,351
15,221
13,969
42,624
53,753
43,642
219,966
197,313
190,682
202,360
183,876
164,660
141,219
114,623
86,473
84,708
73,395
227,520
200,842
246,515
437,113
416,564
386,193
386,193416,564437,113246,515200,842227,52073,39584,70886,473114,623141,219164,660183,876202,360190,682197,313219,96643,64253,75342,62413,96915,22120,35126,63334,02131,67337,99445,02036,61833,88838,75244,07848,0364,6216,41402,61802,088
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,168
20,302
37,699
44,793
67,410
78,415
94,820
94,82078,41567,41044,79337,69920,30216,16800000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,324
2,103
4,320
7,940
9,252
9,985
15,135
15,1359,9859,2527,9404,3202,10310,32400000000000000000000000000000000
   > Long-term Assets 
0
0
43
0
208
1,172
43
83
91
164
214
213
206
199
256
186
186
181
164
142
210
204
170
178
170
357
2,109
1,868
1,610
1,574
1,267
1,730
76,581
86,574
85,835
84,730
91,952
89,094
83,973
83,97389,09491,95284,73085,83586,57476,5811,7301,2671,5741,6101,8682,1093571701781702042101421641811861862561992062132141649183431,17220804300
       Property Plant Equipment 
0
0
0
0
11
14
17
25
34
104
101
94
87
79
68
71
69
64
52
40
41
35
31
35
30
40
1,792
1,551
1,292
1,251
944
1,407
1,302
1,012
1,143
809
8,148
8,039
7,618
7,6188,0398,1488091,1431,0121,3021,4079441,2511,2921,5511,79240303531354140526469716879879410110434251714110000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,897
11,897
10,310
10,310
12,042
12,042
12,042
12,04212,04212,04210,31010,31011,89711,89700000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
62,874
61,268
59,661
58,089
56,500
54,893
53,286
53,28654,89356,50058,08959,66161,26862,87400000000000000000000000000000000
       Other Assets 
0
0
42
0
0
1,159
26
57
57
59
113
119
119
120
188
115
117
117
112
102
169
169
140
144
140
357
2,109
317
317
323
-426,142
0
507
12,398
14,721
15,522
0
14,120
0
014,120015,52214,72112,3985070-426,1423233173172,109357140144140169169102112117117115188120119119113595757261,159004200
> Total Liabilities 
4,125
0
5,989
0
14,087
2,234
2,632
3,914
5,104
6,736
16,641
17,131
16,288
15,779
18,838
15,353
14,716
15,383
14,441
26,527
30,495
37,617
41,827
41,644
36,746
68,368
72,341
70,611
71,828
73,881
70,843
73,862
165,360
181,596
221,920
277,367
332,834
331,349
397,259
397,259331,349332,834277,367221,920181,596165,36073,86270,84373,88171,82870,61172,34168,36836,74641,64441,82737,61730,49526,52714,44115,38314,71615,35318,83815,77916,28817,13116,6416,7365,1043,9142,6322,23414,08705,98904,125
   > Total Current Liabilities 
4,125
0
973
0
1,530
2,234
2,632
3,914
5,104
6,736
7,171
8,356
8,211
8,404
12,175
9,421
9,526
10,943
10,822
7,710
13,070
18,509
24,495
26,100
23,002
20,342
23,438
21,683
22,864
24,707
23,065
24,550
42,570
60,283
96,561
100,652
114,974
114,662
138,854
138,854114,662114,974100,65296,56160,28342,57024,55023,06524,70722,86421,68323,43820,34223,00226,10024,49518,50913,0707,71010,82210,9439,5269,42112,1758,4048,2118,3567,1716,7365,1043,9142,6322,2341,530097304,125
       Short-term Debt 
0
0
41
0
0
0
0
0
0
0
269
1,080
1,896
2,717
3,269
3,275
3,280
3,286
3,291
536
2,155
649
2,602
4,568
6,547
0
1,221
1,197
1,089
880
621
967
709
417
425
108
350
438
1,267
1,2674383501084254177099676218801,0891,1971,22106,5474,5682,6026492,1555363,2913,2863,2803,2753,2692,7171,8961,08026900000004100
       Short Long Term Debt 
0
0
4,483
0
0
0
0
0
0
0
269
9,855
9,973
2,717
3,269
3,275
3,280
3,286
3,291
536
2,155
649
2,602
4,568
6,547
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000006,5474,5682,6026492,1555363,2913,2863,2803,2753,2692,7179,9739,85526900000004,48300
       Accounts payable 
159
0
758
0
1,074
1,716
1,892
1,830
3,035
3,868
4,081
4,741
4,039
2,943
3,435
3,875
3,175
4,167
3,687
3,434
6,137
9,447
10,943
12,192
9,363
11,315
13,504
14,622
11,612
13,382
13,149
12,595
19,431
12,845
38,605
35,770
42,958
29,098
40,679
40,67929,09842,95835,77038,60512,84519,43112,59513,14913,38211,61214,62213,50411,3159,36312,19210,9439,4476,1373,4343,6874,1673,1753,8753,4352,9434,0394,7414,0813,8683,0351,8301,8921,7161,07407580159
       Other Current Liabilities 
140
0
137
0
455
518
740
2,083
2,069
2,868
587
400
285
473
3,124
353
708
577
526
437
531
792
683
1,127
1,212
9,026
8,713
5,865
10,163
10,445
9,295
10,987
22,430
47,022
57,531
64,774
6,342
6,672
96,908
96,9086,6726,34264,77457,53147,02222,43010,9879,29510,44510,1635,8658,7139,0261,2121,1276837925314375265777083533,1244732854005872,8682,0692,08374051845501370140
   > Long-term Liabilities 
0
0
5,016
0
12,557
0
0
0
0
0
9,470
8,775
8,077
7,375
6,663
5,932
5,191
4,440
3,619
18,818
17,425
19,108
17,333
15,544
13,744
48,026
48,904
48,928
48,964
49,174
49,090
49,313
122,789
121,313
125,359
176,715
217,860
216,687
258,405
258,405216,687217,860176,715125,359121,313122,78949,31349,09049,17448,96448,92848,90448,02613,74415,54417,33319,10817,42518,8183,6194,4405,1915,9326,6637,3758,0778,7759,4700000012,55705,01600
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
9,470
8,775
8,077
7,375
6,663
5,932
5,191
4,440
3,619
18,818
17,425
19,108
17,333
15,544
13,744
0
48,322
48,598
48,883
49,174
49,090
49,313
93,459
93,913
0
147,615
176,820
0
0
00176,820147,615093,91393,45949,31349,09049,17448,88348,59848,322013,74415,54417,33319,10817,42518,8183,6194,4405,1915,9326,6637,3758,0778,7759,4700000000000
       Other Liabilities 
0
0
575
0
0
42
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29,330
27,400
31,100
29,100
0
31,550
0
031,550029,10031,10027,40029,33000000000000000000000000000420057500
       Deferred Long Term Liability 
0
0
43
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000004300
> Total Stockholder Equity
0
0
-3,203
0
-7,212
3,904
-18,789
41,235
34,904
28,183
-47,641
29,280
22,755
16,839
-76,585
12,586
-89,671
743
-107,550
17,374
-131,953
6,823
-175,895
-208,380
154,243
-249,631
-278,796
96,293
71,437
42,718
-409,199
14,698
15,199
157,361
109,556
111,812
278,804
269,508
190,977
190,977269,508278,804111,812109,556157,36115,19914,698-409,19942,71871,43796,293-278,796-249,631154,243-208,380-175,8956,823-131,95317,374-107,550743-89,67112,586-76,58516,83922,75529,280-47,64128,18334,90441,235-18,7893,904-7,2120-3,20300
   Retained Earnings -835,571-736,920-674,721-607,551-596,333-535,093-490,270-448,831-409,199-375,223-340,340-308,056-278,796-249,631-226,707-208,380-175,895-151,089-131,953-118,191-107,550-97,953-89,671-81,390-76,585-69,154-62,721-55,636-47,641-40,313-33,118-24,655-18,789-15,392-12,4990-8,22900
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
67,538
68,020
68,494
69,211
84,915
85,473
85,991
93,300
93,974
96,678
98,693
108,485
135,561
156,232
157,908
354,614
364,533
380,946
0
392,585
404,346
411,773
417,937
424,826
463,526
505,465
692,450
0
719,359
953,520
0
0
00953,520719,3590692,450505,465463,526424,826417,937411,773404,346392,5850380,946364,533354,614157,908156,232135,561108,48598,69396,67893,97493,30085,99185,47384,91569,21168,49468,02067,5380000000
   Treasury Stock000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue270,600
Cost of Revenue-32,899
Gross Profit237,701237,701
 
Operating Income (+$)
Gross Profit237,701
Operating Expense-420,608
Operating Income-182,907-182,907
 
Operating Expense (+$)
Research Development97,485
Selling General Administrative323,123
Selling And Marketing Expenses0
Operating Expense420,608420,608
 
Net Interest Income (+$)
Interest Income0
Interest Expense-6,453
Other Finance Cost-0
Net Interest Income-6,453
 
Pretax Income (+$)
Operating Income-182,907
Net Interest Income-6,453
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-238,278-127,536
EBIT - interestExpense = -189,360
-238,278
-232,785
Interest Expense6,453
Earnings Before Interest and Taxes (EBIT)-182,907-231,825
Earnings Before Interest and Taxes (EBITDA)-176,073
 
After tax Income (+$)
Income Before Tax-238,278
Tax Provision-960
Net Income From Continuing Ops-239,238-239,238
Net Income-239,238
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses453,507
Total Other Income/Expenses Net-55,3716,453
 

Technical Analysis of Axsome
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Axsome. The general trend of Axsome is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Axsome's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Axsome Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 83.89 < 98.40.

The bearish price targets are: 68.65 > 64.84 > 56.75.

Tweet this
Axsome Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Axsome Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Axsome Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Axsome Therapeutics Inc. The current macd is -2.78318655.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Axsome price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Axsome. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Axsome price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Axsome Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAxsome Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Axsome Therapeutics Inc. The current adx is 25.92.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Axsome shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Axsome Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Axsome Therapeutics Inc. The current sar is 71.42.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Axsome Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Axsome Therapeutics Inc. The current rsi is 32.24. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Axsome Therapeutics Inc Daily Relative Strength Index (RSI) ChartAxsome Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Axsome Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Axsome price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Axsome Therapeutics Inc Daily Stochastic Oscillator ChartAxsome Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Axsome Therapeutics Inc. The current cci is -120.44353855.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Axsome Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAxsome Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Axsome Therapeutics Inc. The current cmo is -45.99240351.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Axsome Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAxsome Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Axsome Therapeutics Inc. The current willr is -99.21144961.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Axsome Therapeutics Inc Daily Williams %R ChartAxsome Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Axsome Therapeutics Inc.

Axsome Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Axsome Therapeutics Inc. The current atr is 3.25781707.

Axsome Therapeutics Inc Daily Average True Range (ATR) ChartAxsome Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Axsome Therapeutics Inc. The current obv is 53,277,674.

Axsome Therapeutics Inc Daily On-Balance Volume (OBV) ChartAxsome Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Axsome Therapeutics Inc. The current mfi is 15.92.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Axsome Therapeutics Inc Daily Money Flow Index (MFI) ChartAxsome Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Axsome Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Axsome Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Axsome Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.237
Ma 20Greater thanMa 5073.654
Ma 50Greater thanMa 10078.431
Ma 100Greater thanMa 20079.108
OpenGreater thanClose69.440
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Axsome with someone you think should read this too:
  • Are you bullish or bearish on Axsome? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Axsome? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Axsome Therapeutics Inc

I send you an email if I find something interesting about Axsome Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Axsome Therapeutics Inc.

Receive notifications about Axsome Therapeutics Inc in your mailbox!